Log in or register to see all Alerts
New HTA Decisions in Germany
December 2020
Drug name
TAVLESSE® (fostamatinib)
Company
Grifols Deutschland GmbH
Decision date
01/10/2020
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and immune system conditions: general and other
G-BA decision date
15/12/2020
Orphan Drug?
No
Decision
Additional benefit not quantifiable
Indication
Adult patients with chronic immune thrombocytopenia who are resistant to other types of treatment. Main comparators: eltrombopag or romiplostim.
Decision Detail
Main study: NA Main driver of decision: The placebo-controlled studies provided by the company were deemed inappropriate for benefit assessment as they do not allow comparison with the relevant comparators.
Summary
IQWiG concluded that there was insufficient appropriate data provided to make a benefit assessment. The G-BA will decide on the additional benefit.